About Thomas

Thomas has been a member since August 6th 2010, and has created 99 posts from scratch.

Thomas's Jabber Messenger is lovemyducks

Thomas's Bio

We are a fundraising and M&A strategy firm looking investments and fi great opportunities in the Technology,life sciences,sports consulting and entertainment(tv & film) area. We help companies form strategies and grow their businesses

Thomas's Websites

This Author's Website is

Thomas's Recent Articles

How do you value a company?

“®”This question, or variations of it, should be answered by talking about 2 primary valuation methodologies:

a. Intrinsic value (discounted cash flow valuation)
b. Relative valuation (comparables/multiples valuation)

Intrinsic value (DCF)
This approach is the more academically respected approach. The DCF says that the value of a productive asset equals the present value of its cash flows. The answer should run along the line of “project free cash flows for 5-20 years, depending on the availability and reliability of information, and then calculate a terminal value. Discount both the free cash flow projections and terminal value by an appropriate cost of capital (weighted average cost of capital for unlevered DCF and cost of equity for levered DCF). In an unlevered DCF (the more common approach) this will yield the company’s enterprise value (aka firm and transaction value), from which we need to subtract net debt to arrive at equity value. Divide equity value by diluted shares outstanding to arrive at equity value per share.

Relative valuation (Multiples)
The second approach involves determining a comparable peer group – companies that are in the same industry with similar operational, growth, risk, and return on capital characteristics. Truly identical companies of course do not exist, but you should attempt to find as close to comparable companies as possible. Calculate appropriate industry multiples. Apply the median of these multiples on the relevant operating metric of the target company to arrive at a valuation.

Regulation S


The Regulation S Offering (Reg. S) is an exemption designed by the SEC for companies seeking to raise capital from investors located OUTSIDE of the United States.


YES. Unlike the restrictions imposed by Regulation D, a U.S. company or any person acting on its behalf seeking to raise capital utilizing Regulation S exemption MAY:

• Use any form of non-US “general solicitation” or “general advertising”
• Use foreign investor direct mailing lists
• Pay non-U.S. finders fees
• Place tombstone ads in foreign magazines and newspapers


• Preparing a Foreign Private Placement Memorandum
• Preparing a Foreign Subscription Agreement with all Reg S disclaimers
• Preparing an Foreign Offering Circular
• Purchaser Qualifying Questionnaire prepared for non-U.S. investors
• Financial Spreadsheet
• Tracking Spreadsheet
• Designing a password-protected SEC compliant web page
• List of countries which permit the sale of private placement securities
• List of foreign newspapers and magazine publications
• Design a tombstone placement advertisement
• Inclusion for one year in a foreign angel investors network
• Introduction to foreign placement agents and capital finders


BioZhena Corp

FDA-cleared electronic medical monitor for women at home, with data sharing for women’s healthcare providers. We pro
vide an affordable, simple-to-use means of self-monitoring women’s reproductive status (via folliculogenesis = mechanism of menstrual cycles), around which revolves much in women’s health and lifestyle. A strong demand exists for a simple and affordable device that provides reliable data, and that addresses pertinent health, ethical and religious concerns.

Company Overview
Our earlier proof-of-concept studies demonstrated a simple-to-use personal sensor device to help women get pregnant by reliably determining the only 3 days during which “fertile window” pregnancy can be achieved – or avoided. The electronic sensor with said unprecedented ability is ready to be manufactured and launched in the large Trying-To-Conceive Market, and it also has the unique feature of automatically detecting pregnancy right after conception. The superior characteristics will mean that we shall largely displace the currently-available inferior fertility tools (ovulation predictor kits and monitors), and not only that. Because of the way our sensor works, it will also offer unheard of applications such as built-in screening for cervical cancer and other STDs. In fact, we are introducing not a single product but a medical technology platform with numerous applications (yes, much like the smart phones).

Problem to be solved
Womens’ healthcare lacks high quality women’s-specific diagnostic tools for use at home. The difficulty to conceive a child has become a big problem in the decades after the introduction of the contraceptive pill in the 1960s.
Currently available fertility testing products offer only partial and imperfect solutions and under-serve the market. Existing conception-aiding products generally have low levels of accuracy, reliability and information content.
There is no competition for our personal sensor technology in the market segment of fertility awareness for birth control. Cervical health screening is a complex, very unpleasant and expensive clinical procedure, with no home-use tools available. There are no other products with the attributes of our Ovulona (for personal use) and of our Ovulograph (for professional use).

Our core technology, the Ovulona personal fertility monitor for home use, is a combination of a proprietary tissue biosensor and proprietary algorithm based on a unique way of tapping into the mechanism underlying menstrual cycling. The Ovulona anticipates ovulation and also detects ovulation, a fundamental breakthrough.
Also fundamental is the high profit margin inherent in the Ovulona design, which in high quantities will cost less than $20/unit (even less than $10) to make while the sale price will be on the order of $200/unit.
The derivative technology of the Ovulograph is a data management system for optional use by medical professionals (downloaded data from patients). Menstrual cycling history in terms of folliculogenesis is much more meaningful than the old BBT temperature

Tools ‹ Venture Capital Advisors — WordPress

Tools ‹ Venture Capital Advisors — WordPress.

Tools ‹ Venture Capital Advisors — WordPress

Tools ‹ Venture Capital Advisors — WordPress.

control the marketing of your product or service . find the people who will need it the most and let them be involved in the bringing it out into the market .enlist them as part of the team .

invest in customer acquisition

Never enter into nor invest in a business ,  research every part of the customer acquisition and motivation. Execute the plan with passion and talk to as many people as you can . Plan and manage your life the same way

hello everyone
todays tip

get out of the office and try a different market or go to a different group ie:if you deal with restaurants go to a deli  or if you are whole sale go direct to customers